Summary

• No prospective, randomized, head-to-head clinical trials comparing the efficacy and safety of AKEEGA with olaparib have been conducted.
• Results from a matching-adjusted indirect comparison (MAIC) study utilized data from the phase 3 registrational studies, MAGNITUDE (AKEEGA and androgen deprivation therapy [ADT] vs placebo/abiraterone acetate plus prednisone [AAP] and ADT), PROpel (olaparib plus AAP and ADT vs placebo plus AAP and ADT), and TALAPRO-2 (talazoparib plus enzalutamide and ADT vs placebo plus enzalutamide and ADT) have been reported.¹ 

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and DerwentDrug File (and/or other resources, including internal/external databases) was conducted on 19 May 2025. Summarized in this response are relevant data pertaining to this topic in patients with prostate cancer. Due to methodological differences and other potential limitations including scope, timing, study designs and statistical approaches, network meta-analyses and meta-analyses have been excluded in this response. Additional data beyond these parameters may be available in the literature.